AbbVie (ABBV) EPS (Weighted Average and Diluted) (2012 - 2026)
AbbVie (ABBV) reported EPS (Weighted Average and Diluted) of $0.39 for Q1 2026, down 45.83% year-over-year from $0.72 in Q1 2025, and down 61.76% quarter-over-quarter from $1.02 in Q4 2025.
AbbVie (ABBV) EPS (Weighted Average and Diluted) (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.39 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.39, down 45.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.03 (down 13.62% YoY), and the FY2025 annual result was $2.36, down 1.26% from the prior year.
- EPS (Weighted Average and Diluted) eased to $0.39 in Q1 2026 per ABBV's latest filing, from $1.02 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $2.51 in Q1 2022 and troughed at -$0.02 in Q4 2024.
- A 5-year average of $0.85 and a median of $0.77 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2024 and 2025: EPS (Weighted Average and Diluted) tumbled 104.35% in 2024, then jumped 5200.0% in 2025.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.38 in 2022, then sank by 66.67% to $0.46 in 2023, then slumped by 104.35% to -$0.02 in 2024, then jumped by 5200.0% to $1.02 in 2025, then slumped by 61.76% to $0.39 in 2026.
- Business Quant data shows ABBV's EPS (Weighted Average and Diluted) at $0.39 in Q1 2026, $1.02 in Q4 2025, and $0.1 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.31 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.39 |
| Dec 31, 2025 | 1.02 |
| Sep 30, 2025 | 0.10 |
| Jun 30, 2025 | 0.52 |
| Mar 31, 2025 | 0.72 |
| Dec 31, 2024 | -0.02 |
| Sep 30, 2024 | 0.88 |
| Jun 30, 2024 | 0.77 |
| Mar 31, 2024 | 0.77 |
| Dec 31, 2023 | 0.46 |
| Sep 30, 2023 | 1.00 |
| Jun 30, 2023 | 1.14 |
| Mar 31, 2023 | 0.13 |
| Dec 31, 2022 | 1.38 |
| Sep 30, 2022 | 2.21 |
| Jun 30, 2022 | 0.51 |
| Mar 31, 2022 | 2.51 |
| Dec 31, 2021 | 2.26 |
| Sep 30, 2021 | 1.78 |
| Jun 30, 2021 | 0.42 |